a triple-combination mutant of alteplase derived via recombinant DNA established from Chinese Hampster Ovary cells
longer plasma half life (20min vs 7min and terminal half life is 130min)
drug product info. sheet recommends lower heparin doses than are standard:
single IV bolus dose dependent on weight, given over 10sec else Mx as for tPA:
NB. incompatible with dextrose, use NSaline infusions only in that cannula concurrently
more fibrin-specific than alteplase ⇒ less non-cerebral bleed & better mortality in subgroup of pts where Rx started > 4hrs
less non-cerebral bleeding than r-TPA (ASSENT-2 trial)
introduced in Aust. 2000
single bolus tenectaplase (TNK) at dose of 0.25mg/kg appears to be non-inferior to alteplase for Mx of stroke:
easier to administer
longer half-life (3x as longer and even longer terminal half life)
more fibrin specific (14x)
less drop in systemic fibrinogen levels (10x)
more resistant to PAI-1 (80x)
more potent
less MMPp9 activation
possibly safer
less expensive
-